SWOG S1007

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Breast



A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer

S1007 Circulating Biomarker Assessment for Late Relapse Translational Medicine (CBALR TM Substudy (Step 3))is activated effective July 27, 2021.

S1007 will be permanently closed to accrual for Step 1 registration effective October 1, 2015 at 11:59 p.m. PST. The study will be permanently closed to accrual for Step 2 registration effective October 15, 2015 at 11:59 p.m. PST. Patients who will be registered to Step 1 and Step 2 at the same time (patients whose Recurrence Score is already known) must be registered prior to closure of Step 1
registration on October 1, 2015.


Leave a Reply